How Epic Bio is leveraging CRISPR without cutting DNA

April 30, 2026

33 min episode · 2 min read

Stanley Chee

Episode

33 min

Read time

2 min

AI-Generated Summary

Published Apr 30, 2026

Key Takeaways

✓Mutation-agnostic targeting: Epigenetic editing can treat diseases with hundreds of distinct mutations in a single gene — like cystic fibrosis, which has over 2,000 mutations — using one therapeutic modality. Rather than developing separate drugs per mutation variant, a single epigenetic silencing or activation approach targets a common genomic region, bypassing the commercial and clinical feasibility barriers of ultra-rare mutation subgroups.
✓Reversibility as a safety mechanism: Unlike permanent DNA sequence edits, epigenetic modifications can be written and erased because natural cellular machinery includes both writer and eraser enzymes for marks like methylation. This built-in reversibility reduces the risk of irreversible off-target edits — a key safety advantage over standard CRISPR gene editing in clinical settings where remediation options are limited.
✓Miniaturized Cas protein enables single-vector delivery: EpicBio's proprietary CasMini protein is one-third the size of Cas9, small enough to fit an entire GEMS therapeutic — guide RNA plus epigenetic enzyme fusion — into a single AAV vector. This single-vector delivery is critical for in vivo gene therapy, where payload size constraints have historically limited what can be packaged and delivered efficiently.
✓FSHD as a proof-of-concept disease: EPI-321 targets FSHD by re-silencing the DUX4 gene via DNA methylation installation at its promoter region. FSHD is caused by inappropriate DUX4 expression across multiple gene copies — a structure resistant to standard gene editing — making it a strategically selected first indication to validate both epigenetic silencing efficacy and safety in human Phase 1 trials.
✓Pipeline diversification across delivery modalities: Beyond AAV-delivered muscle and retinal programs, EpicBio encodes epigenetic editing molecules in mRNA packaged in lipid nanoparticles for liver disease indications — the same LNP delivery platform used in approved vaccines. This dual-modality approach (AAV for post-mitotic tissues, LNP for liver) expands addressable disease categories without requiring entirely new delivery infrastructure.

What It Covers

Stanford bioengineering professor Stanley Qi, founder of EpicBio, explains how the company's GEMS platform uses a miniaturized Cas protein — one-third the size of Cas9 — to perform reversible epigenetic editing without cutting DNA, with lead program EPI-321 targeting FSHD muscular dystrophy in an upcoming Phase 1 trial.

Key Questions Answered

•Mutation-agnostic targeting: Epigenetic editing can treat diseases with hundreds of distinct mutations in a single gene — like cystic fibrosis, which has over 2,000 mutations — using one therapeutic modality. Rather than developing separate drugs per mutation variant, a single epigenetic silencing or activation approach targets a common genomic region, bypassing the commercial and clinical feasibility barriers of ultra-rare mutation subgroups.
•Reversibility as a safety mechanism: Unlike permanent DNA sequence edits, epigenetic modifications can be written and erased because natural cellular machinery includes both writer and eraser enzymes for marks like methylation. This built-in reversibility reduces the risk of irreversible off-target edits — a key safety advantage over standard CRISPR gene editing in clinical settings where remediation options are limited.
•Miniaturized Cas protein enables single-vector delivery: EpicBio's proprietary CasMini protein is one-third the size of Cas9, small enough to fit an entire GEMS therapeutic — guide RNA plus epigenetic enzyme fusion — into a single AAV vector. This single-vector delivery is critical for in vivo gene therapy, where payload size constraints have historically limited what can be packaged and delivered efficiently.
•FSHD as a proof-of-concept disease: EPI-321 targets FSHD by re-silencing the DUX4 gene via DNA methylation installation at its promoter region. FSHD is caused by inappropriate DUX4 expression across multiple gene copies — a structure resistant to standard gene editing — making it a strategically selected first indication to validate both epigenetic silencing efficacy and safety in human Phase 1 trials.
•Pipeline diversification across delivery modalities: Beyond AAV-delivered muscle and retinal programs, EpicBio encodes epigenetic editing molecules in mRNA packaged in lipid nanoparticles for liver disease indications — the same LNP delivery platform used in approved vaccines. This dual-modality approach (AAV for post-mitotic tissues, LNP for liver) expands addressable disease categories without requiring entirely new delivery infrastructure.

Notable Moment

Qi points out that over 40% of diseases involve genetic or epigenetic changes, and with more than 8,000 rare genetic diseases collectively affecting 6% of the global population, current gene editing addresses only a narrow slice — framing epigenetic editing as a necessary expansion, not merely an alternative approach.

Know someone who'd find this useful?